Related Experiment Video
Updated: Jun 2, 2025
07:37
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
2.6K
Stereotactic Radiosurgery for World Health Organization Grade 2 and 3 Oligodendroglioma: An International Multicenter
Anne-Marie Langlois1, Christian Iorio-Morin1, Justiss Kallos2
1Department of Surgery, Division of Neurosurgery, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke , Québec , Canada.
Neurosurgery
|January 14, 2025
Summary
Stereotactic radiosurgery (SRS) shows promise for treating oligodendrogliomas, a type of primary brain tumor. This study found SRS to be a reasonable management option, with survival rates improving over time post-treatment.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Neurosurgery
Background:
- Oligodendrogliomas are primary brain tumors defined by specific genetic markers (IDH-mutant, 1p19q-codeleted) per the 2021 WHO classification.
- Standard treatments include surgery, radiotherapy, and chemotherapy.
- Stereotactic radiosurgery (SRS) is an appealing focal therapy option for these typically locally recurring, less infiltrative tumors.
Purpose of the Study:
- To evaluate the efficacy of stereotactic radiosurgery (SRS) for oligodendroglioma.
- To collect and analyze retrospective multicenter data on tumor control, clinical response, and morbidity after SRS.
- To determine progression-free survival (PFS) and overall survival (OS) following SRS for oligodendroglioma.
Main Methods:
- Retrospective analysis of 55 patients with grade 2 or 3 oligodendroglioma who underwent single-fraction SRS.
- Data collected from eight institutions via the International Radiosurgery Research Foundation.
- Primary endpoints: PFS and OS. Secondary endpoints: clinical evolution and adverse radiation events. Statistical analyses included Kaplan-Meier and Cox regression.
Main Results:
- Median PFS was 17 months; 5-year actuarial PFS was 24%. Factors associated with worse PFS included WHO grade 3, prior treatments, and higher SRS dose.
- Median OS was 58 months; 5-year actuarial OS was 49%.
- Karnofsky Performance Status remained stable in 51% of patients. Symptomatic radiation-induced changes occurred in a small subset (4/55 patients).
Conclusions:
- Stereotactic radiosurgery (SRS) is a viable treatment option for oligodendroglioma.
- The study supports SRS as a reasonable management strategy for this brain tumor type.
- Further research may refine SRS protocols for optimal outcomes in oligodendroglioma patients.
